PMID- 34193090
OWN - NLM
STAT- MEDLINE
DCOM- 20211129
LR  - 20211129
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jun 30
TI  - Anti-TIF1 gamma-positive IPAF patient developed stage IVB lung squamous carcinoma 
      in 1 year: a case report.
PG  - 204
LID - 10.1186/s12890-021-01570-y [doi]
LID - 204
AB  - BACKGROUND: Patients with connective tissue disease, such as dermatomyositis 
      (DM), and positive anti-TIF1gamma self-antibodies are commonly diagnosed with 
      malignant tumors as a comorbidity. The relationship between anti-TIF1gamma 
      self-antibodies and existing malignant tumors has been confirmed by several 
      reports. However, interstitial pneumonia with autoimmune features (IPAF) cases 
      with a positive anti-TIF1gamma self-antibody developing to solid malignant tumors are 
      rarely reported now. CASE PRESENTATION: Herein, we presented an IPAF patient with 
      anti-TIF1gamma self-antibodies. No evidence of malignant tumors was found at the 
      initial visit. However, the patient had developed stage IVB lung squamous cell 
      carcinoma at the 1-year follow-up review. CONCLUSIONS: Altogether, this report 
      described a rare case of IPAF patient with anti-TIF1gamma self-antibodies developed 
      to advanced lung squamous cell carcinoma in 1 year. The present case highlights 
      more frequent imaging examinations to identify the occurrence of malignant tumors 
      as early as possible in IPAF patients with positive anti-TIF1gamma self-antibodies.
FAU - Xie, Jiao-Jiao
AU  - Xie JJ
AD  - Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing 
      Medical University, Chongqing, 400010, People's Republic of China.
FAU - Li, Bin
AU  - Li B
AD  - Department of Respiratory and Critical Care Medicine, People's Hospital of 
      Fengjie, Chongqing, 404600, Fengjie, People's Republic of China.
FAU - Xu, Rui
AU  - Xu R
AUID- ORCID: 0000-0003-0458-9548
AD  - Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing 
      Medical University, Chongqing, 400010, People's Republic of China. 
      chongyixurui@163.com.
FAU - Du, Xian-Zhi
AU  - Du XZ
AD  - Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing 
      Medical University, Chongqing, 400010, People's Republic of China.
FAU - He, Jin-Zhi
AU  - He JZ
AD  - Department of Respiratory and Critical Care Medicine, People's Hospital of 
      Fengjie, Chongqing, 404600, Fengjie, People's Republic of China.
LA  - eng
GR  - 81500015/Young Scientists Fund/
GR  - X2821/Chongqing Medical University/
PT  - Case Reports
PT  - Journal Article
DEP - 20210630
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - 0 (Autoantibodies)
RN  - 0 (TRIM33 protein, human)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Aged
MH  - Autoantibodies/blood
MH  - Carcinoma, Squamous Cell/*diagnosis/pathology
MH  - Disease Progression
MH  - Humans
MH  - Lung Diseases, Interstitial/*complications/immunology
MH  - Lung Neoplasms/*diagnosis/pathology
MH  - Male
MH  - Neoplasm Staging
MH  - Time Factors
MH  - Tomography, X-Ray Computed
MH  - Transcription Factors/immunology
PMC - PMC8242283
OTO - NOTNLM
OT  - Anti-TIF1gamma self-antibody
OT  - Case report
OT  - IPAF
OT  - Lung carcinoma
OT  - Squamous cell carcinoma
COIS- There are no conflicts of interest to declare.
EDAT- 2021/07/02 06:00
MHDA- 2021/11/30 06:00
PMCR- 2021/06/30
CRDT- 2021/07/01 05:42
PHST- 2021/05/11 00:00 [received]
PHST- 2021/06/18 00:00 [accepted]
PHST- 2021/07/01 05:42 [entrez]
PHST- 2021/07/02 06:00 [pubmed]
PHST- 2021/11/30 06:00 [medline]
PHST- 2021/06/30 00:00 [pmc-release]
AID - 10.1186/s12890-021-01570-y [pii]
AID - 1570 [pii]
AID - 10.1186/s12890-021-01570-y [doi]
PST - epublish
SO  - BMC Pulm Med. 2021 Jun 30;21(1):204. doi: 10.1186/s12890-021-01570-y.